CorRen Medical empowers physicians by providing precise, reliable data for the diagnosis of peripheral artery disease (PAD), addressing the challenges posed by inconsistent test results. UltraSense, an AI-driven ultrasound technology, is designed for the early detection of PAD, a condition that disproportionately impacts marginalized communities.
Update: CorRen Medical raised $130K in December, finalized its superior UltraSense probe design, and is progressing on NIH, FDA, and fundraising efforts. With 65% of its $2M seed round complete, CorRen seeks introductions to close the round by early 2025.
Mike McCormick is the cofounder of CorRen Medical. Mike is a seasoned executive with more than 25 years of experience leading medical device companies and serving on the boards of both private and publicly traded life science companies. Driven by a personal connection, Mike is deeply committed to advancing early diagnosis of peripheral artery disease (PAD). Mike’s grandfather experienced a PAD-related amputation, which fuels his passion and drive for CorRen Medical.